Hologic

Hologic Misses Q4 Revenue Estimates, Sales Rise 2.5% YoY to $1.05B

豪洛捷

Hologic Q1 FY26 revenue up 2.5% to $1,047.8mln.

Lumos Diagnostics Experiences Surge in US FebriDx Sales, FDA Waiver Decision on Track

Hologic Q4 2026 Earnings Preview: Expected EPS of $1.10 and Revenue of $1.07B

Hologic's Price Targets Revisited: Analysts Reassess the Company's Position

Catalyst<ul> <li>Most analysts rate HOLX Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Fund flows show negative trends at the extra-large order size, while smaller orders remain positive.</li></ul>

Key Factors

Hologic (HOLX) reported Q1 revenue of $1.05 billion, missing the $1.07 billion consensus estimate by $20 million.Non-GAAP earnings per share for Hologic (HOLX) came in at $1.04, falling short of the $1.09 analyst estimate by $0.05.Hologic (HOLX) reported Q4 CY2025 revenue of $1.05 billion, a 2.5% year-over-year increase but below analyst expectations.

HOLX News